Ginkgo Bioworks Holdings (DNA) Stock Forecast and Price Target (2026)

Sell-side coverage follows trading volume and banking relationships, so smaller companies, recent listings, and names outside the major indices often carry little or none. That is the situation with DNA. It says nothing about the quality of the business, but it does mean there is no informed average to anchor to, and that any single target you find elsewhere is one analyst's model rather than a consensus.

Ginkgo trades at about 5.4 times trailing sales with no earnings, so the valuation rests on whether revenue stabilizes near the ~$20 million quarterly run rate and losses keep shrinking toward the breakeven target. The stock is up about 21% in 2026 and about 34% over the past month on autonomous-lab and Datapoints news, but it remains down about 30% over the past year and sits well below its 52-week high of $18.22. Figures are from Yahoo Finance as of October 16, 2026; verify live numbers before acting.

For the fiscal year ending Dec 2026, the 3 analysts publishing estimates on DNA expect earnings of -$2.93 per share and revenue of $85.1 million (-50%).

Estimates are the most widely published forecast there is: many more analysts model a company's earnings than publish a price target on it. They are also revised constantly, and the direction of those revisions into a report is often more informative than the level. Ginkgo Bioworks Holdings next reports around November 5, 2026 (an estimated date), which is when these figures get tested against actual results.

Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering DNA do not put out a 2030 number. Anything presenting one is extrapolating a growth rate rather than reporting research, and a figure produced that way tells you about the assumption chosen, not about the company.

What can be said over a long horizon is what the current price already assumes about the business, which is a question the filings answer and a forecast cannot.

That is the more useful frame for a ten-year question. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether Ginkgo Bioworks Holdings can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.

In short: the drivers cited most often are AI, autonomous labs, and Datapoints, Cost restructuring toward breakeven, Focus after the Biosecurity divestiture. The risk cited most often against it is the dominant risk is cash burn against an uncertain path to profitability: Ginkgo remains deeply unprofitable, revenue has kept falling year over year (Q2 2026 revenue was down about 48%), and it is spending down its cash (about $302 million at June 30, 2026, against about $404 million of debt including leases) while promising breakeven that has not yet arrived.

Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the DNA is it a buy page. This page deliberately stops at the numbers.